These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11569256)

  • 1. [Apudocytes in experimental cholera vaccination].
    Bugorkova SA; Isupov IV; Nazarova LS; Eliseev IuIu
    Zh Mikrobiol Epidemiol Immunobiol; 2001; (4):27-31. PubMed ID: 11569256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunomorphologic study of experimental enteric anc combined vaccination against cholera].
    Nazarova LS; Isupov IV; Dzhaparidze MN; Pavlova LP; Gor'kova AV
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Nov; (11):78-82. PubMed ID: 160172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The APUD-system function of the intestines and the morphological changes in the internal organs of adult rabbits infected with toxigenic Vibrio cholerae].
    Bugorkova SA; Isupov IV; Bugorkova TV; Maĭorov NV; Kutyrev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2000; (3):11-4. PubMed ID: 10925863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The comparative characteristics of the pathogenic action of Vibrio cholerae of the non-O1 group O139 serovar and of the O1 group on the intestinal APUD system of suckling rabbits].
    Bugorkova SA; Gracheva IV; Isupov IV; Valova TV; Plotnikov OP
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (3):10-3. PubMed ID: 10851981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative protective efficacy of rZot and rAce combination in challenge experiments with wild type Vibrio cholerae in mouse model.
    Anvari S; Najar-Peerayeh S; Behmanesh M; Bakhshi B
    Hum Vaccin Immunother; 2018; 14(9):2323-2328. PubMed ID: 29852089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of lipopolysaccharide-mimicking peptides and their immunoprotectivity against Vibrio cholerae serogroup O1.
    Mohammad Pour Ghazi F; Gargari SL
    J Pept Sci; 2016 Nov; 22(11-12):682-688. PubMed ID: 27766741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholera vaccine inactivated oral.
    Drugs R D; 1999 Sep; 2(3):193-4. PubMed ID: 10641223
    [No Abstract]   [Full Text] [Related]  

  • 11. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Kaper JB; Levine MM
    J Infect Dis; 1992 Oct; 166(4):837-41. PubMed ID: 1527420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
    Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
    Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholera as a model for research on mucosal immunity and development of oral vaccines.
    Holmgren J; Czerkinsky C
    Curr Opin Immunol; 1992 Aug; 4(4):387-91. PubMed ID: 1388838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.
    Albert MJ; Alam K; Ansaruzzaman M; Qadri F; Sack RB
    J Infect Dis; 1994 Jan; 169(1):230-1. PubMed ID: 8277193
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunogenicity of Vibrio cholerae outer membrane vesicles secreted at various environmental conditions.
    Adriani R; Mousavi Gargari SL; Nazarian S; Sarvary S; Noroozi N
    Vaccine; 2018 Jan; 36(2):322-330. PubMed ID: 29191736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG DNA, liposome and refined antigen oral cholera vaccine.
    Leelawongtawon R; Somroop S; Chaisri U; Tongtawe P; Chongsa-nguan M; Kalambaheti T; Tapchaisri P; Pichyangkul S; Sakolvaree Y; Kurazono H; Hayashi H; Chaicumpa W
    Asian Pac J Allergy Immunol; 2003 Dec; 21(4):231-9. PubMed ID: 15198341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles.
    Yeh MK; Liu YT; Chen JL; Chiang CH
    J Control Release; 2002 Aug; 82(2-3):237-47. PubMed ID: 12175740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.